Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-threo DOPS (DroxiDopa) for Orthostatic Hypotension in Multiple System Atrophy
NCT02071459Phase 3Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jan 2014
- Primary completion
- Oct 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple system atrophy (MSA) and orthostatic hypotension (OH) comparing L-Threo DOPS with Placebo (2 arms). Primary endpoint: Evaluate the efficacy of long term efficacy of L-threo DOPS at 12 weeks. Started Jan 2014; status: completed.
02
Drugs
droxidopa
03
Conditions
multiple system atrophy (MSA)orthostatic hypotension (OH)
Beyond the preview
Go deeper on NCT02071459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02071459.